In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson's treatment and more.
Read the full coverage here:
COVID-19 patients at risk for neurological complications 1 year post-infection
Patients with back pain benefited from at-home VR program
FDA requests further analysis of Supernus Parkinson's treatment
Erenumab not effective at reducing pain in trigeminal neuralgia
Multiple factors indicate need for additional care after concussion
References:
Andersen ASS, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00294-0.
Hou BQ, et al. Clin J Sport Med. 2022;doi:10.1097/JSM.0000000000001057.
Maddox T, et al. At-home virtual reality program for chronic low back pain: Durability of a randomized, placebo-controlled trial to 18-months post-treatment. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022.
